Eptinezumab
Eptinezumab is a humanized monoclonal antibody. Eptinezumab binds to calcitonin gene-related peptide (CGRP) and blocks its interaction with the receptor. Eptinezumab can be used in the study of preventing migraines[1][2].
Product Specifications
CAS Number
1644539-04-7
Product Name Alternative
ALD-403
UNSPSC
12352203
Target
CGRP Receptor
Type
Inhibitory Antibodies
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/eptinezumab.html
Purity
99.90
Solubility
H2O
Smiles
[Eptinezumab]
Molecular Weight
(143.36 kDa)
References & Citations
[1]Dhillon S. Eptinezumab: First Approval. Drugs. 2020;80 (7) :733-739.|[2]LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD) : National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Eptinezumab. 2021 Jul 9.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
